- Home
- HSCS vs XBIO Comparison
HSCS vs XBIO Comparison
Compare HSCS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- XBIO
- Stock Information
- Founded
- HSCS 2007
- XBIO N/A
- Country
- HSCS United States
- XBIO United States
- Employees
- HSCS N/A
- XBIO N/A
- Industry
- HSCS Medical Specialities
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- XBIO Health Care
- Exchange
- HSCS Nasdaq
- XBIO Nasdaq
- Market Cap
- HSCS 3.7M
- XBIO 4.2M
- IPO Year
- HSCS 2022
- XBIO N/A
- Fundamental
- Price
- HSCS $3.57
- XBIO $3.87
- Analyst Decision
- HSCS Strong Buy
- XBIO Hold
- Analyst Count
- HSCS 2
- XBIO 1
- Target Price
- HSCS $13.00
- XBIO N/A
- AVG Volume (30 Days)
- HSCS 50.6K
- XBIO 178.6K
- Earning Date
- HSCS 07-28-2025
- XBIO 08-12-2025
- Dividend Yield
- HSCS N/A
- XBIO N/A
- EPS Growth
- HSCS N/A
- XBIO N/A
- EPS
- HSCS N/A
- XBIO N/A
- Revenue
- HSCS N/A
- XBIO $2,582,728.00
- Revenue This Year
- HSCS N/A
- XBIO $14.23
- Revenue Next Year
- HSCS N/A
- XBIO $7.14
- P/E Ratio
- HSCS N/A
- XBIO N/A
- Revenue Growth
- HSCS 261.17
- XBIO 5.63
- 52 Week Low
- HSCS $2.36
- XBIO $2.20
- 52 Week High
- HSCS $5.30
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- HSCS 46.34
- XBIO 60.67
- Support Level
- HSCS $3.63
- XBIO $3.52
- Resistance Level
- HSCS $3.92
- XBIO $4.09
- Average True Range (ATR)
- HSCS 0.31
- XBIO 0.54
- MACD
- HSCS -0.02
- XBIO 0.09
- Stochastic Oscillator
- HSCS 8.75
- XBIO 45.17
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.